• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

    10/3/24 6:30:00 AM ET
    $ANGO
    Medical/Dental Instruments
    Health Care
    Get the next $ANGO alert in real time by email

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024.

    Fiscal Year 2025 First Quarter Highlights

     

    Quarter Ended

    August 31, 2024

    Pro Forma* YoY Growth

    Net Sales

    $67.5 million

    1.1%

    Med Tech Net Sales

    $28.0 million

    8.7%

    Med Device Net Sales

    $39.5 million

    (3.6)%

    • GAAP gross margin of 54.4%
    • GAAP loss per share of $0.31
    • Adjusted loss per share of $0.11
    • Submitted for FDA 510(k) clearance for Prostate Tissue indication for NanoKnife
    • Received CE Mark Approval in Europe for the Auryon System
    • Initiated RECOVER-AV Clinical Trial in Europe for AlphaVac

    *Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC and Midline product portfolios divested in February 2024, as well as the discontinued Radiofrequency and Syntrax products in February 2024.

    "We are pleased with our strong start to fiscal year 2025, particularly in our Med Tech segment, with Auryon and AlphaVac both delivering over 20% growth in the quarter," commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. "We continue to view 2025 as an inflection point in the trajectory of our business. We expect to continue to deliver strong revenue growth within our Med Tech business as we execute on key commercial initiatives. We remain focused on executing our growth strategy and advancing our innovative product portfolio."

    Fiscal Year 2025 First Quarter Financial Results

    Unless otherwise noted, all financial metrics and growth rates presented below are on a pro forma basis.

    Net sales for the first quarter of fiscal year 2025 were $67.5 million, an increase of 1.1% compared to the prior-year quarter.

    Med Tech net sales were $28.0 million, an 8.7% increase from $25.7 million in the prior-year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform, which includes the AlphaVac and AngioVac mechanical thrombectomy systems, and the NanoKnife irreversible electroporation platform.

    Growth was driven by Auryon sales during the quarter of $13.7 million, which increased 24.9% and AlphaVac sales of $2.2 million, an increase of 21.1% over the prior year. NanoKnife sales were $5.1 million during the quarter, a decrease of 6.9% compared to the prior year period, primarily due to the timing of international orders during last year.

    Med Device net sales were $39.5 million, a decrease of 3.6% compared to $41.0 million in the prior-year period. U.S. net sales of Med Device products grew 2.1% during the first quarter compared to last year.

    U.S. net sales in the first quarter of fiscal 2025 were $59.5 million, an increase of 6.2% from $56.0 million a year ago. International net sales were $8.0 million, a decrease of 25.4%, compared to $10.7 million a year ago, primarily due to the timing of international orders during last year.

    Gross margin for the first quarter of fiscal 2025 was 54.4%, which was 40 basis points down compared to the first quarter of fiscal 2024, and 10 basis points sequentially up from 54.3% in the fourth quarter of fiscal 2024.

    Gross margin for the Med Tech business was 63.3%, a decrease of 160 basis points from the first quarter of fiscal 2024 due to increased capital placements and inflationary costs. Gross margin for the Med Device business was 48.2%, a decrease of 40 basis points compared to the first quarter of fiscal 2024 due to inflationary pressures and costs associated with the transition to outsourced manufacturing.

    The Company recorded a GAAP net loss of $12.8 million, or a loss per share of $0.31, in the first quarter of fiscal 2025. Excluding the items shown in the non-GAAP reconciliation table below, adjusted net loss for the first quarter of fiscal 2025 was $4.4 million, or a loss per share of $0.11. This compares to an adjusted net loss during the fiscal first quarter of 2024 of $6.2 million, or a loss per share of $0.16.

    Adjusted EBITDA in the first quarter of fiscal 2025, excluding the items shown in the non-GAAP reconciliation table below, was $(0.2) million, compared to $(1.1) million in the first quarter of fiscal 2024.

    In the first quarter of fiscal 2025, the Company used $18.3 million in operating cash. The Company's first fiscal quarter has historically exhibited the highest utilization of cash and the first quarter of fiscal 2025 was in line with the Company's expectations.

    At August 31, 2024, the Company had $55.0 million in cash and cash equivalents compared to $76.1 million in cash and cash equivalents at May 31, 2024.

    NanoKnife System's PRESERVE Study Results Submitted for FDA 510(k) Clearance

    In September, the Company submitted results from its Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population (PRESERVE) to the U.S. Food and Drug Administration (FDA) for 510(k) indication of its NanoKnife System in the ablation of prostate tissue in an intermediate-risk population. The comprehensive study enrolled and treated 121 patients across 17 facilities throughout the United States.

    CE Mark Approval in Europe for the Auryon System

    Prior to the end of the quarter AngioDynamics received European CE Mark approval for its Auryon Atherectomy System. This regulatory approval allows AngioDynamics to market the Auryon System in Europe for the treatment of Peripheral Artery Disease (PAD), including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR). The Auryon System uses solid-state laser technology to treat PAD lesions and occlusions. It has been cleared by the FDA since 2020 and has treated over 50,000 patients in the United States. The system is designed to treat lesions of various types, lengths, and locations, both above and below the knee. This CE Mark approval expands AngioDynamics' potential market reach, as the global PAD market is valued at $1.1 billion.

    RECOVER-AV Clinical Trial

    Subsequent to the end of the first fiscal quarter, the Company initiated its RECOVER-AV clinical trial, marking a significant step in evaluating the AlphaVac F18⁸⁵ System for treating acute, intermediate-risk pulmonary embolism (PE) in the European market. This multi-center, multi-national study will assess the efficacy, safety, and long-term functional outcomes of the system across up to 20 hospital sites in Europe. Following the successful APEX-AV study in the United States, RECOVER-AV aims to further demonstrate the system's capabilities in a region where PE prevalence is notably higher. The trial will track patient outcomes over a 12-month period, focusing on key efficacy and safety endpoints.

    Fiscal Year 2025 Financial Guidance

    For fiscal year 2025, the Company continues to expect:

    • Net sales to be in the range of $282 to $288 million, representing growth of between 4.2% – 6.4% over fiscal 2024 pro forma revenue of $270.7 million
    • Med Tech net sales are expected to grow in the range of 10% to 12%
    • Med Device net sales are expected to grow in the range of 1% to 3%
    • Gross margin to be approximately 52% to 53%
    • Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal year 2024
    • Adjusted loss per share in the range of $0.38 to $0.42, compared to pro forma adjusted loss per share of $0.45 in fiscal year 2024

    Conference Call

    The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international).

    This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

    A recording of the call will also be available, until Thursday, October 10, 2024 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13748896.

    Use of Non-GAAP Measures

    Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported pro forma results, adjusted EBITDA, adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

    About AngioDynamics, Inc.

    AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients.

    The Company's innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

    Safe Harbor

    This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

    In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

    ANGIODYNAMICS, INC. AND SUBSIDIARIES

    CONSOLIDATED INCOME STATEMENTS

    (in thousands, except per share data)

     

    Three Months Ended

     

    Three Months Ended

     

    Actual (1)

     

    Pro Forma

    Adjustments (2)

     

    Pro Forma

     

    As Reported (1)

     

    Pro Forma

    Adjustments (2)

     

    Pro Forma

     

    Aug 31, 2024

     

    Aug 31, 2024

     

    Aug 31, 2024

     

    Aug 31, 2023

     

    Aug 31, 2023

     

    Aug 31, 2023

     

     

     

    (unaudited)

     

     

     

     

     

    (unaudited)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net sales

    $

    67,491

     

     

     

    9

     

     

    $

    67,500

     

     

    $

    78,679

     

     

     

    (11,935

    )

     

    $

    66,744

     

    Cost of sales (exclusive of intangible amortization)

     

    30,767

     

     

     

    (2

    )

     

     

    30,765

     

     

     

    38,619

     

     

     

    (8,482

    )

     

     

    30,137

     

    Gross profit

     

    36,724

     

     

     

    11

     

     

     

    36,735

     

     

     

    40,060

     

     

     

    (3,453

    )

     

     

    36,607

     

    % of net sales

     

    54.4

    %

     

     

     

     

    54.4

    %

     

     

    50.9

    %

     

     

     

     

    54.8

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Operating expenses

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

    6,285

     

     

     

    —

     

     

     

    6,285

     

     

     

    7,941

     

     

     

    (207

    )

     

     

    7,734

     

    Sales and marketing

     

    25,605

     

     

     

    —

     

     

     

    25,605

     

     

     

    27,368

     

     

     

    (1,487

    )

     

     

    25,881

     

    General and administrative

     

    10,975

     

     

     

    —

     

     

     

    10,975

     

     

     

    10,856

     

     

     

    (1

    )

     

     

    10,855

     

    Amortization of intangibles

     

    2,570

     

     

     

    —

     

     

     

    2,570

     

     

     

    3,625

     

     

     

    (964

    )

     

     

    2,661

     

    Change in fair value of contingent consideration

     

    76

     

     

     

    —

     

     

     

    76

     

     

     

    (130

    )

     

     

    —

     

     

     

    (130

    )

    Acquisition, restructuring and other items, net

     

    4,311

     

     

     

    154

     

     

     

    4,465

     

     

     

    3,212

     

     

     

    (22

    )

     

     

    3,190

     

    Total operating expenses

     

    49,822

     

     

     

    154

     

     

     

    49,976

     

     

     

    52,872

     

     

     

    (2,681

    )

     

     

    50,191

     

    Gain on sale of assets

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    47,842

     

     

     

    (47,842

    )

     

     

    —

     

    Operating income (loss)

     

    (13,098

    )

     

     

    (143

    )

     

     

    (13,241

    )

     

     

    35,030

     

     

     

    (48,614

    )

     

     

    (13,584

    )

    Interest income, net

     

    606

     

     

     

    —

     

     

     

    606

     

     

     

    119

     

     

     

    —

     

     

     

    119

     

    Other expense, net

     

    (173

    )

     

     

    —

     

     

     

    (173

    )

     

     

    (288

    )

     

     

    —

     

     

     

    (288

    )

    Total other income (expense), net

     

    433

     

     

     

    —

     

     

     

    433

     

     

     

    (169

    )

     

     

    —

     

     

     

    (169

    )

    Income (loss) before income tax benefit

     

    (12,665

    )

     

     

    (143

    )

     

     

    (12,808

    )

     

     

    34,861

     

     

     

    (48,614

    )

     

     

    (13,753

    )

    Income tax expense (benefit)

     

    133

     

     

     

    —

     

     

     

    133

     

     

     

    (11,023

    )

     

     

    —

     

     

     

    (11,023

    )

    Net income (loss)

    $

    (12,798

    )

     

    $

    (143

    )

     

    $

    (12,941

    )

     

    $

    45,884

     

     

    $

    (48,614

    )

     

    $

    (2,730

    )

     

     

     

     

     

     

     

     

     

     

     

     

    Earnings (loss) per share

     

     

     

     

     

     

     

     

     

     

     

    Basic

    $

    (0.31

    )

     

     

     

    $

    (0.32

    )

     

    $

    1.15

     

     

     

     

    $

    (0.07

    )

    Diluted

    $

    (0.31

    )

     

     

     

    $

    (0.32

    )

     

    $

    1.15

     

     

     

     

    $

    (0.07

    )

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted average shares outstanding

     

     

     

     

     

     

     

     

     

     

     

    Basic

     

    40,653

     

     

     

     

     

    40,653

     

     

     

    39,842

     

     

     

     

     

    39,842

     

    Diluted

     

    40,653

     

     

     

     

     

    40,653

     

     

     

    39,968

     

     

     

     

     

    39,842

     

    (1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended August 31, 2024 and 2023.

    (2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

    ANGIODYNAMICS, INC. AND SUBSIDIARIES

    GAAP TO NON-GAAP RECONCILIATION

    (in thousands, except per share data)

    Reconciliation of Net Income (Loss) to non-GAAP Adjusted Net Loss:

     

     

     

    Three Months Ended

     

    Aug 31, 2024

     

    Aug 31, 2023

     

    (unaudited)

     

     

     

     

    Net income (loss)

    $

    (12,798

    )

     

    $

    45,884

     

     

     

     

     

    Amortization of intangibles

     

    2,570

     

     

     

    3,625

     

    Change in fair value of contingent consideration

     

    76

     

     

     

    (130

    )

    Acquisition, restructuring and other items, net (1)

     

    4,311

     

     

     

    3,212

     

    Gain on sale of assets

     

    —

     

     

     

    (47,842

    )

    Tax effect of non-GAAP items (2)

     

    1,446

     

     

     

    (9,580

    )

    Adjusted net loss

    $

    (4,395

    )

     

    $

    (4,831

    )

     

     

     

     

    Reconciliation of Diluted Earnings (Loss) Per Share to non-GAAP Adjusted Diluted Loss Per Share:

     

     

     

    Three Months Ended

     

    Aug 31, 2024

     

    Aug 31, 2023

     

    (unaudited)

     

     

     

     

    Diluted earnings (loss) per share

    $

    (0.31

    )

     

    $

    1.15

     

     

     

     

     

    Amortization of intangibles

     

    0.06

     

     

     

    0.09

     

    Change in fair value of contingent consideration

     

    0.00

     

     

     

    0.00

     

    Acquisition, restructuring and other items, net (1)

     

    0.10

     

     

     

    0.08

     

    Gain on sale of assets

     

    —

     

     

     

    (1.20

    )

    Tax effect of non-GAAP items (2)

     

    0.04

     

     

     

    (0.24

    )

    Adjusted diluted loss per share

    $

    (0.11

    )

     

    $

    (0.12

    )

     

     

     

     

    Adjusted diluted sharecount (3)

     

    40,653

     

     

     

    39,842

     

    (1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

    (2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended August 31, 2024 and 2023.

    (3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

    ANGIODYNAMICS, INC. AND SUBSIDIARIES

    GAAP TO NON-GAAP RECONCILIATION (Continued)

    (in thousands, except per share data)

    Reconciliation of Net Income (Loss) to Adjusted EBITDA:

     

     

     

     

     

     

    Three Months Ended

     

    Aug 31, 2024

     

    Aug 31, 2023

     

    (unaudited)

     

     

     

     

    Net income (loss)

    $

    (12,798

    )

     

    $

    45,884

     

     

     

     

     

    Income tax expense (benefit)

     

    133

     

     

     

    (11,023

    )

    Interest income, net

     

    (606

    )

     

     

    (119

    )

    Depreciation and amortization

     

    6,785

     

     

     

    6,688

     

    Change in fair value of contingent consideration

     

    76

     

     

     

    (130

    )

    Stock based compensation

     

    3,205

     

     

     

    4,144

     

    Acquisition, restructuring and other items, net (1)

     

    3,042

     

     

     

    3,212

     

    Gain on sale of assets

     

    —

     

     

     

    (47,842

    )

    Adjusted EBITDA

    $

    (163

    )

     

    $

    814

     

     

     

     

     

    Per diluted share:

     

     

     

    Adjusted EBITDA

    $

    0.00

     

     

    $

    0.02

     

     

     

     

     

    (1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

    ANGIODYNAMICS, INC. AND SUBSIDIARIES

    GAAP TO NON-GAAP RECONCILIATION

    (in thousands, except per share data)

    Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted Net Loss:

     

    Pro Forma

     

    Three Months Ended

     

    Aug 31, 2024

     

    Aug 31, 2023

     

    (unaudited)

     

     

     

     

    Pro forma net loss

    $

    (12,941

    )

     

    $

    (2,730

    )

     

     

     

     

    Amortization of intangibles

     

    2,570

     

     

     

    2,661

     

    Change in fair value of contingent consideration

     

    76

     

     

     

    (130

    )

    Acquisition, restructuring and other items, net (1)

     

    4,465

     

     

     

    3,190

     

    Tax effect of non-GAAP items (2)

     

    1,443

     

     

     

    (9,176

    )

    Adjusted pro forma net loss

    $

    (4,387

    )

     

    $

    (6,185

    )

     

     

     

     

    Reconciliation of Pro Forma Diluted Loss Per Share to Pro Forma Adjusted Diluted Loss Per Share:

     

    Pro Forma

     

    Three Months Ended

     

    Aug 31, 2024

     

    Aug 31, 2023

     

    (unaudited)

     

     

     

     

    Pro forma diluted loss per share

    $

    (0.32

    )

     

    $

    (0.07

    )

     

     

     

     

    Amortization of intangibles

     

    0.06

     

     

     

    0.07

     

    Change in fair value of contingent consideration

     

    0.00

     

     

     

    0.00

     

    Acquisition, restructuring and other items, net (1)

     

    0.11

     

     

     

    0.08

     

    Tax effect of non-GAAP items (2)

     

    0.04

     

     

     

    (0.24

    )

    Adjusted pro forma diluted loss per share

    $

    (0.11

    )

     

    $

    (0.16

    )

     

     

     

     

    Adjusted diluted sharecount (3)

     

    40,653

     

     

     

    39,842

     

    (1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

    (2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended August 31, 2024 and 2023.

    (3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

    ANGIODYNAMICS, INC. AND SUBSIDIARIES

    GAAP TO NON-GAAP RECONCILIATION (Continued)

    (in thousands, except per share data)

    Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted EBITDA:

     

     

     

     

    Pro Forma

     

    Three Months Ended

     

    Aug 31, 2024

     

    Aug 31, 2023

     

    (unaudited)

     

     

     

     

    Pro forma net loss

    $

    (12,941

    )

     

    $

    (2,730

    )

     

     

     

     

    Income tax expense (benefit)

     

    133

     

     

     

    (11,023

    )

    Interest income, net

     

    (606

    )

     

     

    (119

    )

    Depreciation and amortization

     

    6,785

     

     

     

    5,682

     

    Change in fair value of contingent consideration

     

    76

     

     

     

    (130

    )

    Stock based compensation

     

    3,205

     

     

     

    4,058

     

    Acquisition, restructuring and other items, net (1)

     

    3,196

     

     

     

    3,190

     

    Adjusted EBITDA

    $

    (152

    )

     

    $

    (1,072

    )

     

     

     

     

    Per diluted share:

     

     

     

    Adjusted EBITDA

    $

    0.00

     

     

    $

    (0.03

    )

     

     

     

     

    (1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

    ANGIODYNAMICS, INC. AND SUBSIDIARIES

    ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET DETAIL

    (in thousands)

     

    Three Months Ended

    (in thousands)

    Aug 31, 2024

     

    Aug 31, 2023

    Legal (1)

    $

    507

     

     

    $

    1,817

     

    Plant closure (2)

     

    3,589

     

     

     

    —

     

    Transition service agreement (3)

     

    (507

    )

     

     

    (145

    )

    Manufacturing relocation (4)

     

    —

     

     

     

    587

     

    Other

     

    722

     

     

     

    953

     

    Total

    $

    4,311

     

     

    $

    3,212

     

    (1) Legal expenses related to litigation that is outside the normal course of business.
    (2) Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.
    (3) Transition services agreements that were entered into with Merit and Spectrum.
    (4) Expenses to relocate certain manufacturing lines out of Queensbury, NY.

    ANGIODYNAMICS, INC. AND SUBSIDIARIES

    NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY

    (in thousands)

     

    Three Months Ended

     

    Three Months Ended

     

     

     

     

     

     

     

     

     

    Actual (1)

    Pro Forma

    Adj. (2)

    Pro Forma

     

    As

    Reported (1)

    Pro Forma

    Adj. (2)

    Pro Forma

     

    Actual

     

    Pro Forma

     

    Aug 31,

    2024

    Aug 31,

    2024

    Aug 31,

    2024

     

    Aug 31,

    2023

    Aug 31,

    2023

    Aug 31,

    2023

     

    % Growth

    Currency Impact

    Constant Currency Growth

     

    %

    Growth

    Currency Impact

    Constant Currency Growth

     

    (unaudited)

     

    (unaudited)

     

     

     

     

     

     

     

     

    Net Sales

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Med Tech

    $

    27,969

     

    $

    —

     

     

    $

    27,969

     

    $

    25,860

     

    $

    (131

    )

     

    $

    25,729

     

    8.2

    %

     

     

     

    8.7

    %

     

     

    Med Device

     

    39,522

     

     

    9

     

     

     

    39,531

     

     

    52,819

     

     

    (11,804

    )

     

     

    41,015

     

    (25.2

    )%

     

     

     

    (3.6

    )%

     

     

     

    $

    67,491

     

    $

    9

     

     

    $

    67,500

     

    $

    78,679

     

    $

    (11,935

    )

     

    $

    66,744

     

    (14.2

    )%

    0.0

    %

    (14.2

    )%

     

    1.1

    %

    0.0

    %

    1.1

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net Sales

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    United States

    $

    59,481

     

    $

    10

     

     

    $

    59,491

     

    $

    64,399

     

    $

    (8,395

    )

     

    $

    56,004

     

    (7.6

    )%

     

     

     

    6.2

    %

     

     

    International

     

    8,010

     

     

    (1

    )

     

     

    8,009

     

     

    14,280

     

     

    (3,540

    )

     

     

    10,740

     

    (43.9

    )%

    0.0

    %

    (43.9

    )%

     

    (25.4

    )%

     

     

     

    $

    67,491

     

    $

    9

     

     

    $

    67,500

     

    $

    78,679

     

    $

    (11,935

    )

     

    $

    66,744

     

    (14.2

    )%

    0.0

    %

    (14.2

    )%

     

    1.1

    %

    0.0

    %

    1.1

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    (1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended August 31, 2024 and 2023.

    (2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

    GROSS PROFIT BY PRODUCT CATEGORY

    (in thousands)

     

    Three Months Ended

     

    Three Months Ended

     

     

     

     

     

    Actual (1)

    Pro Forma

    Adj. (2)

    Pro Forma

     

    As Reported (1)

    Pro Forma

    Adj. (2)

    Pro Forma

     

    Actual

     

    Pro Forma

     

    Aug 31,

    2024

    Aug 31,

    2024

    Aug 31,

    2024

     

    Aug 31,

    2023

    Aug 31,

    2023

    Aug 31,

    2023

     

    % Change

     

    % Change

     

    (unaudited)

     

    (unaudited)

     

     

     

     

    Med Tech

    $

    17,697

     

     

    $

    —

     

    $

    17,697

     

     

    $

    16,727

     

     

    $

    (39

    )

     

    $

    16,688

     

     

    5.8

    %

     

    6.0

    %

    Gross profit % of sales

     

    63.3

    %

     

     

     

     

    63.3

    %

     

     

    64.7

    %

     

     

     

     

    64.9

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Med Device

    $

    19,027

     

     

    $

    11

     

    $

    19,038

     

     

    $

    23,333

     

     

    $

    (3,414

    )

     

    $

    19,919

     

     

    (18.5

    )%

     

    (4.4

    )%

    Gross profit % of sales

     

    48.1

    %

     

     

     

     

    48.2

    %

     

     

    44.2

    %

     

     

     

     

    48.6

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Total

    $

    36,724

     

     

    $

    11

     

    $

    36,735

     

     

    $

    40,060

     

     

    $

    (3,453

    )

     

    $

    36,607

     

     

    (8.3

    )%

     

    0.3

    %

    Gross profit % of sales

     

    54.4

    %

     

     

     

     

    54.4

    %

     

     

    50.9

    %

     

     

     

     

    54.8

    %

     

     

     

     

    (1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended August 31, 2024 and 2023.

    (2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

    ANGIODYNAMICS, INC. AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS

    (in thousands)

     

    Aug 31, 2024

     

    May 31, 2024

     

    (unaudited)

     

    (audited)

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    55,005

     

    $

    76,056

    Accounts receivable, net

     

    39,563

     

     

    43,610

    Inventories

     

    64,700

     

     

    60,616

    Prepaid expenses and other

     

    13,326

     

     

    12,971

    Total current assets

     

    172,594

     

     

    193,253

    Property, plant and equipment, net

     

    34,377

     

     

    35,666

    Other assets

     

    10,883

     

     

    11,369

    Intangible assets, net

     

    75,774

     

     

    77,383

    Total assets

    $

    293,628

     

    $

    317,671

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    31,272

     

    $

    37,751

    Accrued liabilities

     

    34,108

     

     

    41,098

    Current portion of contingent consideration

     

    4,804

     

     

    4,728

    Other current liabilities

     

    6,515

     

     

    7,578

    Total current liabilities

     

    76,699

     

     

    91,155

    Deferred income taxes

     

    4,626

     

     

    4,852

    Other long-term liabilities

     

    15,721

     

     

    16,078

    Total liabilities

     

    97,046

     

     

    112,085

    Stockholders' equity

     

    196,582

     

     

    205,586

    Total Liabilities and Stockholders' Equity

    $

    293,628

     

    $

    317,671

     

    ANGIODYNAMICS, INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

     

    Three Months Ended

     

    Aug 31, 2024

     

    Aug 31, 2023

     

    (unaudited)

    Cash flows from operating activities:

     

     

     

    Net income (loss)

    $

    (12,798

    )

     

    $

    45,884

     

    Adjustments to reconcile net income (loss) to net cash used in operating activities:

     

     

     

    Depreciation and amortization

     

    6,785

     

     

     

    6,688

     

    Non-cash lease expense

     

    494

     

     

     

    476

     

    Stock based compensation

     

    3,205

     

     

     

    4,144

     

    Gain on disposal of assets

     

    —

     

     

     

    (47,842

    )

    Transaction costs for disposition

     

    —

     

     

     

    (2,427

    )

    Change in fair value of contingent consideration

     

    76

     

     

     

    (130

    )

    Deferred income taxes

     

    (339

    )

     

     

    (11,415

    )

    Change in accounts receivable allowances

     

    270

     

     

     

    (78

    )

    Fixed and intangible asset impairments and disposals

     

    20

     

     

     

    65

     

    Write-off of other assets

     

    —

     

     

     

    869

     

    Other

     

    121

     

     

     

    (9

    )

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    3,784

     

     

     

    3,157

     

    Inventories

     

    (4,053

    )

     

     

    (4,574

    )

    Prepaid expenses and other

     

    (836

    )

     

     

    (4,168

    )

    Accounts payable, accrued and other liabilities

     

    (14,982

    )

     

     

    (16,539

    )

    Net cash used in operating activities

     

    (18,253

    )

     

     

    (25,899

    )

    Cash flows from investing activities:

     

     

     

    Additions to property, plant and equipment

     

    (1,092

    )

     

     

    (791

    )

    Additions to placement and evaluation units

     

    (1,313

    )

     

     

    (767

    )

    Proceeds from sale of assets

     

    —

     

     

     

    100,000

     

    Net cash (used in) provided by investing activities

     

    (2,405

    )

     

     

    98,442

     

    Cash flows from financing activities:

     

     

     

    Repayment of long-term debt

     

    —

     

     

     

    (50,000

    )

    Payment of acquisition related contingent consideration

     

    —

     

     

     

    (10,000

    )

    Repurchase of common stock

     

    (552

    )

     

     

    —

     

    Proceeds from exercise of stock options and employee stock purchase plan

     

    43

     

     

     

    410

     

    Net cash used in financing activities

     

    (509

    )

     

     

    (59,590

    )

    Effect of exchange rate changes on cash and cash equivalents

     

    116

     

     

     

    13

     

    Increase (decrease) in cash and cash equivalents

     

    (21,051

    )

     

     

    12,966

     

    Cash and cash equivalents at beginning of period

     

    76,056

     

     

     

    44,620

     

    Cash and cash equivalents at end of period

    $

    55,005

     

     

    $

    57,586

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241003678383/en/

    Get the next $ANGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANGO

    DatePrice TargetRatingAnalyst
    4/5/2024$12.00Perform → Outperform
    Oppenheimer
    9/25/2023$19.00Buy
    H.C. Wainwright
    4/17/2023$14.00 → $13.00Strong Buy → Outperform
    Raymond James
    10/15/2021$28.00 → $37.00Hold → Buy
    Canaccord Genuity
    8/20/2021Perform
    Oppenheimer
    7/14/2021$24.00 → $28.00Hold
    Canaccord Genuity
    7/9/2021$27.00 → $32.00Strong Buy
    Raymond James
    More analyst ratings

    $ANGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights   Quarter Ended February 28, 2025 Pro Forma* YoY Growth Pro Forma* Net Sales $72.0 million 9.2% Med Tech Net Sales $31.3 million 22.2% Med Device Net Sales $40.7 million 0.9% GAAP gross margin of 54.0% GAAP loss per share of $(0.11) Adjusted loss per shar

      4/2/25 6:30:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics to Host Virtual Cardiovascular Investor Event

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual Cardiovascular Investor Event Date: Wednesday, April 2, 2025 Time: 9:00am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=c

      3/31/25 8:00:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company's cardiovascular business and products. Fiscal 2025 Third Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate

      3/19/25 8:00:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by AngioDynamics Inc.

      SCHEDULE 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)

      4/14/25 4:11:01 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by AngioDynamics Inc.

      10-Q - ANGIODYNAMICS INC (0001275187) (Filer)

      4/2/25 2:14:31 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ANGIODYNAMICS INC (0001275187) (Filer)

      4/2/25 9:40:35 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP Quality and Regulatory Nighan Warren Jr sold $49,979 worth of shares (4,060 units at $12.31), decreasing direct ownership by 9% to 41,817 units (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      1/17/25 4:05:54 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SVP, Chief Legal Officer Weiss Lawrence T was granted 52,697 shares (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      12/4/24 9:33:45 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Weiss Lawrence T

      3 - ANGIODYNAMICS INC (0001275187) (Issuer)

      12/4/24 9:29:59 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    Financials

    Live finance-specific insights

    See more
    • AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights   Quarter Ended February 28, 2025 Pro Forma* YoY Growth Pro Forma* Net Sales $72.0 million 9.2% Med Tech Net Sales $31.3 million 22.2% Med Device Net Sales $40.7 million 0.9% GAAP gross margin of 54.0% GAAP loss per share of $(0.11) Adjusted loss per shar

      4/2/25 6:30:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics to Host Virtual Cardiovascular Investor Event

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual Cardiovascular Investor Event Date: Wednesday, April 2, 2025 Time: 9:00am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=c

      3/31/25 8:00:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company's cardiovascular business and products. Fiscal 2025 Third Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate

      3/19/25 8:00:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AngioDynamics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded AngioDynamics from Perform to Outperform and set a new price target of $12.00

      4/5/24 7:36:59 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • H.C. Wainwright initiated coverage on AngioDynamics with a new price target

      H.C. Wainwright initiated coverage of AngioDynamics with a rating of Buy and set a new price target of $19.00

      9/25/23 8:09:50 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics downgraded by Raymond James with a new price target

      Raymond James downgraded AngioDynamics from Strong Buy to Outperform and set a new price target of $13.00 from $14.00 previously

      4/17/23 7:20:48 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    Leadership Updates

    Live Leadership Updates

    See more

    $ANGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burgess to the Company's Board of Directors. Ms. Burgess brings over 35 years of management, financial, and global operations experience, including over 15 years at Medtronic, Inc., where she was responsible for the company's Americas Region as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions. "Ms

      7/24/23 4:01:00 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • PAVmed Appoints Shaun O'Neil as Chief Operating Officer

      PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities

      2/24/22 8:25:00 AM ET
      $ANGO
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

      VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an

      6/1/21 4:01:00 PM ET
      $SCL
      $RCEL
      $ANGO
      Package Goods/Cosmetics
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care
    • SVP Quality and Regulatory Nighan Warren Jr bought $5,285 worth of shares (868 units at $6.09), increasing direct ownership by 2% to 45,877 units (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      10/10/24 3:22:57 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • EVP and CFO Trowbridge Stephen A bought $9,962 worth of shares (1,700 units at $5.86), increasing direct ownership by 0.99% to 172,711 units (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      10/8/24 6:27:36 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • President and CEO Clemmer James C bought $120,600 worth of shares (20,000 units at $6.03), increasing direct ownership by 3% to 681,582 units (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      10/8/24 4:32:02 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by AngioDynamics Inc.

      SC 13G - ANGIODYNAMICS INC (0001275187) (Subject)

      5/30/24 4:25:33 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by AngioDynamics Inc. (Amendment)

      SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)

      2/13/24 4:58:53 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by AngioDynamics Inc. (Amendment)

      SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)

      2/9/24 9:58:57 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care